Cargando…

Risk assessment of thromboembolic events in hospitalized cancer patients

Hospitalized cancer patients are at increased risk for Thromboembolic Events (TEs). As untailored thromboprophylaxis is associated with hemorrhagic complications, the definition of a risk-assessment model (RAM) in this population is needed. INDICATE was a prospective observational study enrolling ho...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nichetti, Federico, Ligorio, Francesca, Montelatici, Giulia, Porcu, Luca, Zattarin, Emma, Provenzano, Leonardo, Franza, Andrea, Lalli, Luca, de Braud, Filippo, Platania, Marco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8440577/ https://www.ncbi.nlm.nih.gov/pubmed/34521927 http://dx.doi.org/10.1038/s41598-021-97659-9

Ejemplares similares

Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients
por: Nichetti, Federico, et al.
Publicado: (2019)

Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications
por: Vernieri, Claudio, et al.
Publicado: (2020)

Case Report: Prolonged clinical benefit with sequential trastuzumab-containing treatments in a patient with advanced extramammary Paget disease of the groin
por: Zattarin, Emma, et al.
Publicado: (2022)

Fasting-mimicking diet plus chemotherapy in breast cancer treatment
por: Vernieri, Claudio, et al.
Publicado: (2020)

The pan-immune-inflammation value is associated with clinical outcomes in patients with advanced TNBC treated with first-line, platinum-based chemotherapy: an institutional retrospective analysis
por: Provenzano, Leonardo, et al.
Publicado: (2023)

Prognostic impact of body mass index (BMI) in HER2+ breast cancer treated with anti-HER2 therapies: from preclinical rationale to clinical implications
por: Ligorio, Francesca, et al.
Publicado: (2022)

The Pan-Immune-Inflammation-Value Predicts the Survival of Patients with Human Epidermal Growth Factor Receptor 2 (HER2)—Positive Advanced Breast Cancer Treated with First-Line Taxane-Trastuzumab-Pertuzumab
por: Ligorio, Francesca, et al.
Publicado: (2021)

Antitumor activity and efficacy of shorter versus longer duration of anthracycline-taxane neoadjuvant chemotherapy in stage II–III HER2-negative breast cancer: a 10-year, retrospective analysis
por: Lobefaro, Riccardo, et al.
Publicado: (2020)

Hormone receptor status influences the impact of body mass index and hyperglycemia on the risk of tumor relapse in early-stage HER2-positive breast cancer patients
por: Ligorio, Francesca, et al.
Publicado: (2021)

Oral Capecitabine-Vinorelbine Is Associated with Longer Overall Survival When Compared to Single-Agent Capecitabine in Patients with Hormone Receptor-Positive Advanced Breast Cancer
por: Vernieri, Claudio, et al.
Publicado: (2020)

Hormone Receptor Loss in Breast Cancer: Molecular Mechanisms, Clinical Settings, and Therapeutic Implications
por: Zattarin, Emma, et al.
Publicado: (2020)

Impact of dexamethasone-sparing regimens on delayed nausea caused by moderately or highly emetogenic chemotherapy: a meta-analysis of randomised evidence
por: Celio, Luigi, et al.
Publicado: (2019)

Predictive Biomarkers of Response to Immunotherapy in Metastatic Renal Cell Cancer
por: Raimondi, Alessandra, et al.
Publicado: (2020)

Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors
por: Zattarin, Emma, et al.
Publicado: (2023)

Weighing the prognostic role of hyponatremia in hospitalized patients with metastatic solid tumors: the HYPNOSIS study
por: Fucà, Giovanni, et al.
Publicado: (2019)

Comprehensive transcriptomic analysis to identify biological and clinical differences in cholangiocarcinoma
por: Silvestri, Marco, et al.
Publicado: (2023)

Early thromboembolic events in hospitalized COVID-19 patients
por: Rosen, Raphael J.
Publicado: (2020)

Systemic Treatment of Patients With Gastrointestinal Cancers During the COVID-19 Outbreak: COVID-19-adapted Recommendations of the National Cancer Institute of Milan
por: Pietrantonio, Filippo, et al.
Publicado: (2020)

Efficacy of mRNA anti-SARS-CoV-2 vaccination and dynamics of humoral immune response in patients with solid tumors: results from the institutional registry of an Italian tertiary cancer center
por: Fucà, Giovanni, et al.
Publicado: (2022)

Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma?
por: Grassi, Paolo, et al.
Publicado: (2017)

A Review of Thromboembolic Events in Hospitalized COVID-19 Patients
por: Fontelo, Paul, et al.
Publicado: (2021)

A review of thromboembolic events in hospitalized COVID-19 patients
por: Fontelo, Paul, et al.
Publicado: (2021)

Incidence of Thromboembolic Events in Cancer Hospitalized Patients With COVID-19
por: Rogado, Jacobo, et al.
Publicado: (2021)

Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis
por: Pusceddu, Sara, et al.
Publicado: (2019)

COVID-19 risk for patients undergoing anticancer treatment at the outpatient clinic of the National Cancer Institute of Milan: the COVINT study
por: Nichetti, Federico, et al.
Publicado: (2020)

Thromboembolic and Bleeding Events in Transthyretin Amyloidosis and Coagulation System Abnormalities: A Review
por: Napolitano, Angela, et al.
Publicado: (2023)

Longitudinal Evaluation of Health Plan Cost per Venous Thromboembolism or Bleed Event in Patients With a Prior Venous Thromboembolism Event During Hospitalization
por: Bullano, Michael F., et al.
Publicado: (2005)

Behind Recurrent Thromboembolic Events
por: Guerreiro, Sara, et al.
Publicado: (2016)

Thromboembolic events in polycythemia vera
por: Griesshammer, Martin, et al.
Publicado: (2019)

Thromboembolic events and Covid-19
por: Ribes, Agnès, et al.
Publicado: (2020)

Clozapine-Related Thromboembolic Events
por: Pallares Vela, Elisa, et al.
Publicado: (2021)

A New Risk Prediction Model for Venous Thromboembolism and Death in Ambulatory Lung Cancer Patients
por: Gomez-Rosas, Patricia, et al.
Publicado: (2023)

Caffeine Protects Against Retinal Inflammation
por: Conti, Federica, et al.
Publicado: (2022)

Risk of venous thromboembolic events after COVID-19 infection: a systematic review and meta-analysis
por: Zuin, Marco, et al.
Publicado: (2023)

Venous thromboembolism secondary to hospitalization for COVID-19: patient management and long-term outcomes
por: Ageno, Walter, et al.
Publicado: (2023)

Twelve‐month risk of thromboembolic events in COVID‐19 hospital survivors in Scotland
por: Farrell, J., et al.
Publicado: (2022)

Sarcopenia and monocyte-to-lymphocyte ratio as prognostic factors in early-stage breast cancer
por: Zattarin, Emma, et al.
Publicado: (2020)

Atrial Fibrillation and Cryptogenic Thromboembolic Events
por: Henz, Benhur Davi, et al.
Publicado: (2018)

CONSULTATIVE HEMATOLOGY IN A COVID-19 DEDICATED HOSPITAL: FAR BEYOND THROMBOEMBOLIC EVENTS
por: Brandão, A.A.G.S., et al.
Publicado: (2020)

Vascular thromboembolic events following COVID‐19 hospital discharge: Incidence and risk factors
por: Eswaran, Harish, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_44pj3sapasfvj100mn8r3vrqoq